Bronchial Neoplasms  >>  Conmana (icotinib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Conmana (icotinib) / Betta Pharma
ICOGEN, NCT01040780: Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Checkmark LALCA 2014
Aug 2014 - Aug 2014: LALCA 2014
Checkmark vs. gefitinib in previously treated adv NSCLC
Aug 2013 - Aug 2013: vs. gefitinib in previously treated adv NSCLC
Checkmark P3 data - ESMO 2012
More
Completed
3
399
RoW
Icotinib, BPI-2009, Conmana, Gefitinib, ZD1839, Iressa
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
03/10
12/11
NCT02486354: Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Completed
3
128
RoW
icotinib, Conmana
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
10/11
04/12
NCT01724801: Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Completed
3
176
RoW
whole brain radiation(WBI), Icotinib
Guangdong Association of Clinical Trials, Guangdong Provincial People's Hospital
Brain Metastasis, Non Small Cell Lung Cancer
06/15
09/16
GASTO 1014, NCT02714010: EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Recruiting
3
601
RoW
EGFR-TKI, Gefitinib/Tarceva/Icotinib, whole brain radiotherapy, WBRT
Sun Yat-sen University
Non-Small Cell Lung Cancer
12/21
12/22

Download Options